Evidence map›Paper›PMID 39325813›Full record

ArticlePloS one2024

Production and characterization of homologous protoporphyrinogen IX oxidase (PPO) proteins: Evidence that small N-terminal amino acid changes do not impact protein function.

Cunxi Wang, Meiying Zheng, Chandler Est, Remi Lawal, Wenguang Liang, David A Korasick, Michael J Rau, Scott A Saracco, Virginia Johnson, Yanfei Wang and 5 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Cunxi WangRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.ORCID 0000-0002-7772-6200
Meiying ZhengRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Chandler EstRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.ORCID 0000-0002-5588-9930
Remi LawalRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Wenguang LiangPlant Biotechnology, Bayer Crop Science, Chesterfield, Missouri, United States of America.
David A KorasickSmall Molecules, Bayer Crop Science, Chesterfield, Missouri, United States of America.ORCID 0000-0002-6337-2085
Michael J RauPlant Biotechnology, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Scott A SaraccoRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Virginia JohnsonRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Yanfei WangRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Tommi WhitePlant Biotechnology, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Wenze LiRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Jun ZhangRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Xin GuRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.
Flora Liu-GontarekRegulatory Science, Bayer Crop Science, Chesterfield, Missouri, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transgenic soybean, cotton, and maize tolerant to protoporphyrinogen IX oxidase (PPO)-inhibiting herbicides have been developed by introduction of a bacterial-derived PPO targeted into the chloroplast. PPO is a membrane-associated protein with an intrinsic tendency for aggregation, making expression, purification, and formulation at high concentrations difficult. In this study, transgenic PPO expressed in three crops was demonstrated to exhibit up to a 13 amino acid sequence difference in the N-terminus due to differential processing of the chloroplast transit peptide (CTP). Five PPO protein variants were produced in and purified from E. coli, each displaying equivalent immunoreactivity and functional activity, with values ranging from 193 to 266 nmol min-1 mg-1. Inclusion of an N-terminal 6xHis-tag or differential processing of the CTP peptide does not impact PPO functional activity. Additionally, structural modeling by Alphafold, ESMfold, and Openfold indicates that these short N-terminal extensions are disordered and predicted to not interfere with the mature PPO structure. These results support the view that safety studies on PPO from various crops can be performed from a single representative variant. Herein, we report a novel and robust method for large-scale production of PPO, enabling rapid production of more than 200 g of highly active PPO protein at 99% purity and low endotoxin contamination. We also present a formulation that allows for concentration of active PPO to > 75 mg/mL in a buffer suitable for mammalian toxicity studies.

Indexed as

Protoporphyrinogen OxidaseAmino Acid SequenceEscherichia coliGlycine maxModels, MolecularPlants, Genetically ModifiedZea maysProtoporphyrinogen Oxidase

Identifiers

PMID39325813
PMCPMC11426539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.